News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SYGNIS To Present At Upcoming Investor Conferences



11/21/2016 9:40:35 AM

Madrid, Spain, and Heidelberg, Germany, November 18, 2016 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the attendance at two major German investor conferences in November and December 2016.

German Equity Forum hosted by Deutsche Börse AG

Date of attendance: 21 and 22 November 2016

Presentation time: Monday, 21 November 2016, 17:00 - 17:30 pm CET, Room Oslo

Venue: Frankfurt/Main, Germany, Sheraton Frankfurt Airport Hotel and Conference Center

Presenting and available for meetings: Dr. Heikki Lanckriet, Co-CEO and CSO, Pilar de la Huerta, Co-CEO/CFO

More information: http://www.eigenkapitalforum.com/

22nd Munich Capital Markets Conference (MKK) hosted by GBC AG

Date of attendance: 7 and 8 December 2016

Presentation time: Tuesday, 7 December 2016, 12:20 - 13:00 pm CET, Room GBC III

Venue: Munich, Germany, The Charles Hotel

Presenting and available for meetings: Dr. Heikki Lanckriet, Co-CEO and CSO, Pilar de la Huerta, CEO/CFO

More information: http://www.mkk-investor.de/

If you would like to meet us, please contact for both conferences: contact@mc-services.eu or via phone: +49 89 210 228-0.

For further information, please contact:

SYGNIS AG
Pilar de la Huerta
Co-CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 0
Email: raimund.gabriel@mc-services.eu

About SYGNIS AG: www.sygnis.com

SYGNIS AG is specialized in the development and the commercialization of proprietary technologies and offers a wide range of different commercial products addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has added a complementary proteomic product portfolio. Resulting from this significant expansion, SYGNIS’ product portfolio now covers the entire workflow of molecular biology. The products are sold through a direct sales force and several distribution partners in Europe, the US and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the US as well as sales offices in Asia. The company is listed on the German Stock Exchange in Frankfurt in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES